CN109734921A - A kind of polyethyleneimine-b- polylactic-acid block copolymer, preparation method and application - Google Patents
A kind of polyethyleneimine-b- polylactic-acid block copolymer, preparation method and application Download PDFInfo
- Publication number
- CN109734921A CN109734921A CN201811264453.XA CN201811264453A CN109734921A CN 109734921 A CN109734921 A CN 109734921A CN 201811264453 A CN201811264453 A CN 201811264453A CN 109734921 A CN109734921 A CN 109734921A
- Authority
- CN
- China
- Prior art keywords
- polylactic acid
- preparation
- pla
- high molecular
- polyethyleneimine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is prepared for polyethyleneimine-b- polylactic acid block macromolecular copolymer, and is used for using it as novel carriers while containing the antitumor chemical drug of slightly solubility and nucleic acid drug, and carry out applied research to it.The present invention will be in the connection of the carboxyl end group of the amino of polyethyleneimine and polylactic acid using crosslinking-condensation method, the novel carriers (PEI-PLA) of preparation are safe and non-toxic, with preferable cell-penetrating ability, chemical drug antitumor for slightly solubility has high drug load, well complex nucleus acids drug.The nanoparticle of the antitumor chemical drug of slightly solubility and nucleic acid drug preparation is contained simultaneously with PEI-PLA copolymer with good inhibiting tumour cells effect, therefore, PEI-PLA high molecular polymer has preferable development prospect.
Description
Technical field
The invention belongs to field of biomedical materials, are related to a kind of polymer material, and in particular to polyethyleneimine-b- is poly-
Preparation method, screening and the application of lactic acid block copolymer.
Background technique
The main means of clinical treatment malignant tumour have operation, radiotherapy, chemotherapy etc. at present.Most of chemotherapy are as a kind of
Systemic treatment means, drug can be distributed in whole body most organs and tissue with blood circulation, therefore have to some
Whole body sows Advanced cancers that are tendency or having occurred and that transfer, more suitable for application.However Chemotherapeutic Drugs On Normal group
The high toxicity knitted is still the main reason for limitation chemotherapy is widely applied.Nucleic acid drug is as a kind of novel therapeutic mode, energy
Enough inhibit metastases, reduce drug resistance and drug toxicity, has become the main study subject for the treatment of cancer at present.Especially
RNA interferes the discovery of (RNA interference, RNAi) technology so that the mankind can use siRNA and come specifically " silencing "
The expression of Disease-causing gene, thus can treat the disease of current " routine treatment can not cure ".In the recent period, anti-tumor drug and nucleic acid
The synergistic effect of class drug in cancer treatment, causes the concern of many researchers.People, which imagine, utilizes nano medicament carrying system,
Antitumor chemical drug and nucleic acid drug are delivered in tumor tissues jointly, on the one hand, this double particles that carry can pass through shadow
Ringing Drug-resistant channel improves chemotherapy effect, on the other hand, double nucleic acid carried in particles can silencing correlation oncogene, and
Chemical drug can be done directly on tumour cell, therefore can play the role of double inhibition to the proliferation of tumour cell.Antitumor chemical drug and
The joint delivering of nucleic acid drug has broad prospects in the treatment of cancer.
In order to play synergy, antineoplastic chemotherapy medicine and nucleic acid drug need to act on identical tumour cell
In, but there is limitations for both drugs, this becomes the main problem for hindering the two to carry altogether.Chemotherapeutics majority category
In fat-soluble, non-specific, normal tissue toxic side effect, it is limited to kill tumour cell effect.And nucleic acid recycles in vivo
Half-life short in the middle, stability is poor in blood plasma, is easily degraded by nuclease, in addition, since nucleic acid belongs to hydrophily, negatively charged
Lotus is not easy through fat-soluble, negatively charged cell membrane, therefore causes it to cannot be introduced into tumour cell and play effect.It is above this
A little unfavorable factors limit the common delivering of antitumor chemical drug and nucleic acid drug, thus how to solve the above problems and become
The hot spot of people's research, nano medicament carrying system is biodegradable with its, hypoimmunity, high targeting and dosage form diversification etc.
Advantage has obtained more and more approvals so far.Nano-carrier can be made in conjunction with drug molecule by actively or passively targeting
Drug molecule is located on target organ, is reduced the toxicity or other adverse reactions of normal tissue, them can also be avoided from blood
It is disposed of in liquid circulation.In conclusion containing antitumor chemical drug and nucleic acid drug jointly using nano medicament carrying system, and right
It is further modified, and can reduce the toxic side effect of chemotherapeutics, nucleic acid drug is protected not swallowed by body, and energy
By the distinctive EPR of nano medicament carrying system itself (Enhanced Penetraion Retention) effect, to play passively
Targeting.
Based on the above theoretical and Research foundation, it is intended to and synthesizes a kind of polyethyleneimine-b- polylactic acid block (PEI-
PLA) high molecular polymer contains the antitumor chemical drug and nucleic acid drug of slightly solubility jointly, designs a kind of cancer target nanometer
Drug-loading system is studied and inquires into its application value in lung cancer therapy.Polyethyleneimine (Polyethylenimine, PEI)
It is a kind of hydrophilic cationic polymer, is most common pharmaceutical carrier in gene delivery, has transfection efficiency high, there is " matter
The advantages that son pump " effect, the extensive concern by formulation art.However, PEI excessively high cation concn, so that in drug body
Stability is poor, and toxicity is big.Therefore, by modification reduce its recycle in vivo in toxicity and keep it in tumour cell wear
Permeability is the key that research.Polylactic acid (Polylactic acid, PLA) is strong lipophilic high molecular polymer, with PEG-
PLA is that the taxol micella of carrier is listed in foreign countries, and effect is fine.Studies have shown that this taxol micella can reduce medicine
The toxic side effect of object in the normal tissue improves drugloading rate and increases the stability of drug.PEI-PLA polymer is as one kind two
Parent's property block copolymer independently can fill to form micella, and specific method is to contain insoluble anti-tumor medicament in the hydrophobic side PLA,
Positively charged PEI water-wet side loads electronegative siRNA.
The present invention PEI and PLA synthesizing new block macromolecular polymer, for realizing confrontation tumour chemical drug and nucleic acid
The total load of drug, significantly improves the transfection efficiency of gene and the drugloading rate of anti-tumor drug.Result of study shows synthesized load
Body material small toxicity, PEI-PLA high molecular polymer are capable of forming stable nanoparticle, carry out inside and outside drug effect to the nanoparticle
It learns evaluation and finds that the composite nano-granule can be absorbed efficiently by tumour cell, tumour cell is imitated with good double inhibition
Rate.
Summary of the invention
The technical problem to be solved in the invention is a kind of novel for delivering antitumor chemical drug and nucleic acid medicine jointly
The high molecular polymer of object, cytotoxicity is low, has high drug load and transfection efficiency.
In addition, it is also desirable to provide a kind of novel polyphosphazene polymer for being used to deliver antitumor chemical drug and nucleic acid drug jointly
Close the preparation method of object.
To solve technical problem of the invention, the invention provides the following technical scheme:
There is provided the polyphosphazene polymers that a kind of amine-modified polylactic acid of polyethyleneimine is formed for the one side of technical solution of the present invention
Object PEI-PLA is closed, concrete structure formula general formula is as follows: PEIm-PLAn,
PEIm-PLAn specific structure are as follows:
In formula, m and n respectively indicate ethylene imine chain (part indicated with PEI) and polylactic acid chain (i.e. with PLA table
The part shown) the degree of polymerization.Wherein the degree of polymerization m of ethylene imine chain is 2-200, preferably 4-80, more preferably 6-20；Its
The polymerization degree n of middle polylactic acid chain is 10-300, preferably 7-300, more preferably 14-70.
The molecular weight of polyethyleneimine chain part is 500-50000Da, for example, 1000-20000Da, for example, 1500-
5000Da；Wherein the molecular weight of polylactic acid chain part is 500-20000Da, for example, 1000-10000Da, for example, 1000-
5000Da。
In the present invention, the size of polyglutamic acid chain part and polylactic acid chain part can both be reached with molecular weight form, also can be used
Degree of polymerization expression, as long as they are not in contradiction.When being expressed with the degree of polymerization, bottom right footmark is that a m is that 2-200, n are
The integer without unit of 10-300, such as PEI15-PLA10；When being reached with molecular weight form, bottom right footmark is a 500-50000
Either the number of 3k-50k (for a polyethyleneimine chain part) either 500-20000 or 5k-20k is (for poly-
For lactic acid chain part) number, such as PEI10k-PLA10k, in another example PEI10000-PLA10000。
Polylactic acid is hydrophobic chain, hydrophobic inner core can be formed after connecting with polyethyleneimine, polyethyleneimine is as parent
Water shell, the block copolymer can be self-assembly of micelle-like structures in aqueous solution, and hydrophobic cores can wrap up indissoluble
Property chemical drug, meanwhile, positively charged hydrophily shell polyethyleneimine can with compound electronegative nucleic acid drug,.The system mentions
The stability of high carrier, polylactic acid connection polyethyleneimine can increase the lipophilicity of material, improve the affinity to cell, into
And increase the conveying intracellular of drug.
The present invention also provides the methods for preparing above-mentioned high molecular polymer, include the following steps:
1) PLA-COOH is dissolved in dimethyl sulfoxide (DMSO), 1- (3- dimethylamino-propyl) -3- ethyl carbon is added
Diimmonium salt hydrochlorate (EDC) and N- hydroxysuccinimide (NHS) are used as condensing agent, activate 2-4h at 20-40 DEG C；
2) PEI is added in above-mentioned solution, is added a small amount of triethylamine, at 20-40 DEG C, the reaction was continued 12-48h；
3) dialysis 24-48h after reaction, is carried out with the bag filter that molecular cut off is 100-3000, is freeze-dried, both
Secure satisfactory grades sub- polymer P EI-PLA.
In the preparation method of PEI-PLA high molecular polymer, the ratio of preferred polylactic acid and DMSO are 1g polyethylene
Imines is dissolved in 1-25ml DMSO, and the ratio of preferred polylactic acid and DMSO are that 1g polyethyleneimine is dissolved in 1-10ml
In DMSO；The amount of the triethylamine of addition and the volume ratio of DMSO are 1:20-200, the amount of preferred triethylamine and the volume of DMSO
Than for 1:100-200；The molar ratio of preferred EDC and polylactic acid is 1:1-30, and the molar ratio of preferred EDC and polylactic acid is
1:5-10；The molar ratio of preferred NHS and polylactic acid is 1:1-30, and the molar ratio of preferred NHS and polylactic acid is 1:5-10；
Preferred polylactic acid and the molar ratio of polyethyleneimine can be 1:1-10, it is highly preferred that polylactic acid and polyethyleneimine rub
Your ratio can be 1:1-5.
Another aspect of the invention provides the low molecular weight polyethylene imines of above-mentioned aliphatic group grafting as drug
Delivery vector, especially in vivo, the application of ex-vivo drug delivery carrier or its preparation in vivo, ex-vivo drug delivery carrier
Using, such as delivering slightly solubility antineoplastic chemotherapy medicine, Plasmid DNA, siRNA etc..In one embodiment, above-mentioned
When PEI-PLA is as drug delivery vehicle, the drugloading rate for containing taxol is 1-5%, and the size of the Plasmid DNA of delivering is 1-
The size of 30Kb, the siRNA of delivering are 15-30bp.When the high molecular polymer is used to contain antitumor chemical drug, with dialysis
Prepared by method, the mass ratio of high molecular polymer and antitumor chemical drug is 50:1-5:1, it is furthermore preferred that high molecular polymer with
The mass ratio of antitumor chemical drug selects 15:1-5:1.The high molecular polymer for contain antitumor chemical drug when, DMSO with
The ratio of high molecular polymer is that 1mLDMSO dissolves 5-50mgPEI-PLA, it is furthermore preferred that the ratio of DMSO and high molecular polymer
Example is that 1mLDMSO dissolves 20-30mgPEI-PLA.The high molecular polymer is for being added when containing antitumor chemical drug
The volume ratio of DMSO and water is 1:5-100, it is furthermore preferred that the volume ratio of the DMSO and water that are added are 1:5-20.It is described
High molecular polymer for contain antitumor chemical drug when, selected dialysis bag retention molecular weight be 3000-10000, it is more excellent
Choosing, selected dialysis bag retention molecular weight is 5000-8000.The mass ratio of high molecular polymer and nucleic acid is to transfection efficiency
It has a significant impact.Preferably, the mass ratio of high molecular polymer and nucleic acid selects 1:1-100:1, it is furthermore preferred that high molecular polymerization
The mass ratio of object and nucleic acid selects 1:1-50:1.Under room temperature, PEI-PLA high molecular polymer and indissoluble provided by the invention
Property chemical drug can be self-assembly of micella in DMSO, chloroform, methanol or acetone and other organic solvent；Nucleic acid can HBS buffer,
Compound is compounded to form according to certain mass ratio in HBG buffer, RPMI-1640 cell culture fluid or DMEM cell culture fluid.
Can be administered using intravenous injection using the nanoparticle of high molecular polymer provided by the invention preparation, be instiled in intratracheal,
The administration of the methods of Neulized inhalation and local intratumor injection.
The preparation method and applications of PEI-PLA block copolymer of the present invention have the following beneficial effects:
1) polyethyleneimine is incorporated on the free carboxyl of polylactic acid molecule using one-step synthesis, preparation method letter
It is single；2) anti-tumor drug and gene are contained simultaneously using block copolymer, does not need other auxiliary materials such as cosolvent solubilization agent, brings
Toxic side effect it is small；3) prepared with PEI-PLA the nanoparticle to be formed it is high to the transfection efficiency of gene, to the load medicine of anti-tumor drug
Amount is high；4) uptake ratio that the nanoparticles on tumor cells to be formed is prepared with PEI-PLA is high.
Detailed description of the invention
Fig. 1 is the synthetic route of embodiment 1.
Fig. 2 is preparation gained high molecular polymer PEI-PLA in embodiment 11H-NMR map.
Fig. 3 is the transmission electron microscope figure of preparation gained high molecular polymer PEI-PLA in embodiment 3.
Fig. 4 is according to the cytotoxicity result figure for obtaining carrier material prepared by experimental example 1.
Fig. 5 is according to total load taxol and siRNA prepared by experimental example 2surNanoparticle inhibits cell Proliferation effect in vitro
Figure.
Fig. 6 is according to obtaining total carrying Oregon GreenPTX and siRNA prepared by experimental example 3CY3Nanoparticle is to A549 lung
The ingestion result figure of cancer cell.
Specific embodiment
Embodiment
The synthesis of embodiment 1:PEI-PLA
Weigh 1300mgPLA1.3k- COOH is placed in 50mL round-bottomed flask, and 10mLDMSO dissolution is added.To sufficiently dissolve
Afterwards, 958.5mg EDC (molar ratio with polylactic acid is 1:5), 575.5mg NHS (molar ratio with polylactic acid is 1:5) is added,
2h is reacted at 25 DEG C, activates PLA.It is finished to 2h priming reaction, the 200 μ L triethylamine (volumes with DMSO is added into reaction solution
Than for 1:50), 600mgPEI1.8k(molar ratio with PLA is 3:1), continuation is reacted for 24 hours at 25 DEG C, to after reaction, use
Bag filter (molecular cut off 2500) dialyses 48h in deionized water to get PEI-PLA is arrived, and final product is freeze-dried.
Reaction equation is shown in Fig. 1.Product is obtained after taking appropriate freeze-drying, is dissolved in heavy water (D2O), measure nuclear magnetic resonance spectroscopy (1H-NMR), survey
Determining frequency is 600MHz, as a result sees Fig. 2.
Embodiment 2: the PEI-PLA preparation synthesized with different feed ratio PEI and PLA carries taxol (PTX) nanoparticle
And measure partial size, current potential and drugloading rate
200,300,400,500mgPLA are weighed respectively1.3k- COOH is placed in 50mL round-bottomed flask, and it is molten that appropriate DMSO is added
Solution.To after completely dissolution, be separately added into 590,885,1180,1475mg EDC (molar ratio with polylactic acid is 1:20), 354,
531,708,885mg NHS (molar ratio with polylactic acid is 1:20) reacts 2h at 25 DEG C, activates PLA.It is complete to 2h priming reaction
Finish, a small amount of triethylamine, 278mgPEI are added into reaction solution1.8k(molar ratio with PLA is respectively 1:1,2:1,3:1,4:1),
Continuation is reacted for 24 hours at 25 DEG C, to after reaction, be dialysed in deionized water with bag filter (molecular cut off 2.500Da)
48h to get arrive different degree of substitution PEI-PLA.
A series of above-mentioned PEI-PLA and 5mg PTX of 50mg are weighed, is dissolved in 2mLDMSO is mixed well respectively, are used
Buret is drop by drop added in 20mL water and instills while stirring.After being sufficiently stirred be packed into molecular cut off be 7000 it is saturating
It dialyses in analysis bag for 24 hours afterwards with 0.45 μm of membrane filtration, and is freeze-dried, obtain the different PEI-PLA nanoparticles of load PTX
(PEI-PLA/PTX).After nanoparticle is dissolved with distilled water, 10 times are diluted, composite particles are measured using laser particle analyzer respectively
Particle diameter distribution and zeta current potential.
The different PEI-PLA nanoparticle 10mg for carrying PTX are weighed respectively, acetonitrile 100ml is added, and rotation misfortune 1min dissolution is complete.
Subsequent filtrate after taking 0.45um filtering with microporous membrane is surveyed according to the content of following chromatographic condition and measuring method after same treatment
The fixed concentration to get taxol in nanoparticle, carries out the calculating of drugloading rate according to the following formula.
Chromatographic condition and system suitability are filler with octadecylsilane chemically bonded silica；With methanol-water-acetonitrile
(23:41:36) is mobile phase, Detection wavelength 227nm.10 μ L of system suitability solution under related substance item is taken to inject liquid
The separating degree at chromatography, taxol peak and the peak impurity I and the peak impurity II should be greater than 1.0.
Measuring method precision weighs appropriate (being approximately equivalent to taxol 60mg) above-mentioned nanoparticle, sets in 50ml measuring bottle, adds acetonitrile
Scale is dissolved and be diluted to, is shaken up, is filtered, precision measures subsequent filtrate 5ml, is placed in 50ml measuring bottle, adds dilution in acetonitrile to scale, shake
Even, as test solution, precision measures 10 μ L and injects liquid chromatograph, records chromatogram；Taxol control product separately are taken, add second
Nitrile dissolves and quantifies the solution that dilution is made in every 1ml containing 0.12mg to be measured in the same method as reference substance solution.By external standard method with
Calculated by peak area the results are shown in Table 1 to get, partial size current potential and drugloading rate.
The PEI-PLA high molecular polymer preparation that table 1. is synthesized with different feed ratio PEI and PLA carries paclitaxel nano
Partial size, current potential and the drugloading rate of grain
Embodiment 3:PEI-PLA/PTX/siRNAsurThe preparation and observation form size of composite nano-granule
PEI-PLA high molecular polymer is synthesized according to the content of embodiment 1, and weighs 25mg PEI-PLA and 2.5mg
PTX is dissolved in 1mLDMSO and is mixed well, and is drop by drop added in 10mL water with buret and is instilled while stirring.To
It is fitted into the bag filter that molecular cut off is 7000 and is dialysed for 24 hours afterwards with 0.45 μm of membrane filtration after being sufficiently stirred, and carry out cold
Be lyophilized it is dry, obtain carry PTX PEI-PLA nanoparticle (PEI-PLA/PTX).With DEPC water by survivin siRNA
(siRNAsur) dry powder is dissolved into the solution of 20pmol/ μ L, it is 20:1 according to the mass ratio of polymer and siRNA, by PEI-PLA/
After the aqueous solution of PTX and the survivin siRNA solution of 20pmol/ μ L mix in equal volume, vortex 10s is incubated at room temperature 20min,
Obtain PEI-PLA/PTX/siRNAsurComposite nano-granule.It is added dropwise after above-mentioned composite nano-granule is diluted with water 10 times in wax stone
Surplus liquid is drawn on surface after five minutes, with 2% phosphoric acid tungsten dye liquor negative staining, after drying 15min, transmission electron microscope
(TEM) form and size that composite nano-granule is observed under, are as a result shown in Fig. 3.
Experimental example:
Experimental example 1: the vitro cytotoxicity research of carrier material
With the 4T1 breast cancer cell of 0.25% trypsin digestion monolayer cultivation, it is made into individually with 1640 culture medium of RPMI
Cell suspension, with every hole 4 × 103A cell is inoculated in 96 orifice plates, every 100 μ L of pore volume, under the conditions of 37 DEG C, 5%CO2
Culture is for 24 hours.After for 24 hours, culture medium is sucked, is separately added into PEI-PLA high molecular polymer in PEI containing various concentration and embodiment 1
1640 culture medium of RPMI, 200 μ L, continue respectively culture for 24 hours, suck culture medium after 48h, the MTT (5mg/ of 20 μ L is added in every hole
ML concentration), continue after cultivating 4h, suck solution, 150 μ LDMSO are added, shaking table vibrates 10min.It is with non-dosing object functional hole
Control wells calculate cell survival rate, investigate the cytotoxicity of PEI-PLA carrier material, and 6 repeating holes are arranged in every hole.Microplate reader
Absorption value (A) is measured at 490nm, survival rate cell survival rate %=A is calculated as followsS/Ab× 100%.Wherein, AS、AbRespectively
For the absorption value of administration group and blank group.By calculating cell survival rate, carrier material is investigated to the toxicity of tumour cell, as a result
It is shown in Table 2, Fig. 4.
The cytotoxicity of 2. carrier material of table
Experimental example 2: function siRNA is carriedsurNanoparticle extracorporeal anti-tumor cell Proliferation effect
By the typeⅡ pneumocyte in logarithmic growth phase with 5 × 103The density in/hole is laid in 96 orifice plates, 37 DEG C,
5%CO2Culture is for 24 hours.For 24 hours afterwards by the empty vectors material (PEI-PLA) of same dose, taxol, survivinsiRNA, with
And load effect of nano-paclitaxel (PEI-PLA/PTX), the load survivinsiRNA nanoparticle (PEI- being prepared according to embodiment 3
PLA/siRNAsur) and double load composite nano-granule (PEI-PLA/PTX/siRNAsur) be added and continue to cultivate 48h into corresponding aperture, often
Group sets 6 multiple holes.Culture medium is sucked after 48h, 20 μ L of MTT agent is added in every hole, continues to cultivate 4h, then 150 μ l are added in every hole
DMSO solution.Absorption value (A) is measured at microplate reader 490nm, survival rate cell survival rate (cell is calculated as follows
Viability) %=AS/Ab× 100%.Wherein, AS、AbThe respectively absorption value of administration group and blank group.By calculating cell
Survival rate investigates the killing ability of nanoparticles on tumor cells.The result shows that as shown in table 3, Fig. 5, with other each group of phase
Than PEI-PLA/PTX/siRNAsurThe cell survival rate of group only has 14.70%, has significant difference (P < 0.05*).Therefore,
PEI-PLA/PTX/siRNAsurThere is good inhibitory effect to A549 cell Proliferation.
Table 3. carries nanoparticle altogether and inhibits cell Proliferation effect picture in vitro
Experimental example 3: laser co-focusing observes PEI-PLA/Oregon Green PTX/siRNACY3Composite nano-granule it is thin
Born of the same parents absorb situation
It will be in the A549 cell of logarithmic growth phase, with 10 × 104The density in/hole is laid in 12 orifice plates, 37 DEG C, 5%CO2
Under the conditions of overnight incubation.Using the siRNA of Oregon Green PTX and CY3 label as model drug, PEI-PLA/ is prepared
Oregon Green PTX/siRNACY3Composite nano-granule, and be transfected into corresponding aperture with the hole siRNA dosage 100pmol/, 4h
Afterwards, enter born of the same parents' situation in laser co-focusing observation different time.From intake experimental studies results from (attached drawing 6), with when
Between extension, the born of the same parents' situation that composite nano-granule enters increasingly increases (yl moiety be two kinds of drugs enter born of the same parents' situation jointly), when 4h
It is complete substantially to enter born of the same parents, illustrates that PEI-PLA high molecular polymer can effectively deliver taxol and siRNA into born of the same parents.
Claims (14)
1. a kind of high molecular polymer that the amine-modified polylactic acid of polyethyleneimine is formed, which is characterized in that it is with following general formula:
PEIm-PLAn,
In formula, PEI indicates ethylene imine chain, and PLA indicates polylactic acid chain；M and n respectively indicate ethylene imine chain and polylactic acid
The degree of polymerization of chain；Wherein the degree of polymerization m of ethylene imine chain is 2-200, preferably 4-80, more preferably 6-20；Polylactic acid chain
Polymerization degree n be 10-300, preferably 7-300, more preferably 14-70.
2. high molecular polymer according to claim 1, which is characterized in that wherein the molecular weight of polyethyleneimine chain part is
500-50000Da, preferably 1000-20000Da, more preferably 1500-5000Da；Wherein the molecular weight of polylactic acid chain part is
500-20000Da, preferably 1000-10000Da, more preferably 1000-5000Da.
3. the preparation method of high molecular polymer described in claim 1, which comprises the steps of:
1) polylactic acid chain carboxyl end group is dissolved in dimethyl sulfoxide, 1- (3- dimethylamino-propyl) -3- ethyl carbon two is added
Inferior amine salt hydrochlorate and N- hydroxysuccinimide activate 2-4h at 20-40 DEG C as condensing agent；
2) polyethyleneimine is added in above-mentioned solution 1), is added a small amount of triethylamine, at 20-40 DEG C, the reaction was continued 12-48h；
3) after reaction, using dialysis process, dialysis 24-48h is carried out with the bag filter that molecular cut off is 100-3000, it is cold
It is lyophilized dry, both secured satisfactory grades sub- polymer.
4. 1) preparation method according to claim 3, which is characterized in that polylactic acid and the ratio of dimethyl sulfoxide are 1g polylactic acid
It is dissolved in 1-25ml dimethyl sulfoxide, the ratio of preferred polylactic acid and dimethyl sulfoxide is that 1g polyethyleneimine is dissolved in
In 1-10ml dimethyl sulfoxide.
5. preparation method according to claim 3, which is characterized in that 1- (3- the dimethylamino-propyl) -3- ethyl carbon two of addition
The molar ratio of inferior amine salt hydrochlorate and polylactic acid is 1:1-30, preferred 1- (3- dimethylamino-propyl) -3- ethyl carbodiimide
The molar ratio of hydrochloride and polylactic acid is 1:5-10.
6. preparation method according to claim 3, which is characterized in that the N- hydroxysuccinimide of addition and mole of polylactic acid
Than for 1:1-30, the molar ratio of preferred N- hydroxysuccinimide and polylactic acid is 1:5-10.
7. preparation method according to claim 3, which is characterized in that polylactic acid and the molar ratio of polyethyleneimine can be 1:1-
10, the molar ratio of polylactic acid and polyethyleneimine can be 1:1-5.
8. preparation method according to claim 3, which is characterized in that the amount of the triethylamine of addition and the volume ratio of dimethyl sulfoxide
For 1:20-200, the amount of preferred triethylamine and the volume ratio of dimethyl sulfoxide are 1:100-200.
9. preparation method according to claim 3, which is characterized in that dialysis process first uses 40-60% ethanol solution dialysis 4-6
It is secondary, then with deionized water dialysis 24-48h.
10. application of the high molecular polymer of claim 1 in the common delivery vector for preparing antitumor chemical drug and nucleic acid.
11. application according to claim 10, which is characterized in that the antitumor chemical drug is selected from taxol, Docetaxel,
The nucleic acid is selected from RNA or DNA.
12. application according to claim 10, the high molecular polymer for when containing antitumor chemical drug, with dialysis into
Row preparation, the mass ratio of high molecular polymer and antitumor chemical drug are 50:1-5:1, dimethyl sulfoxide and high molecular polymer
Ratio is 1mL dmso solution 5-50mgPEI-PLA, and the volume ratio of the dimethyl sulfoxide and water that are added is 1:5-
100, selected dialysis bag retention molecular weight is 3000-10000.
13. application according to claim 10, when the high molecular polymer is used for composite nucleic acid, high molecular polymer and core
The mass ratio of acid selects 1:1-100:1.
14. application according to claim 11, which is characterized in that the RNA is selected from siRNA；
The size of the DNA is 1-30Kb；The size of the siRNA is 15-30bp.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711023906 | 2017-10-27 | ||
| CN2017110239065 | 2017-10-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109734921A true CN109734921A (en) | 2019-05-10 |
| CN109734921B CN109734921B (en) | 2021-09-14 |
Family
ID=66354321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811264453.XA Active CN109734921B (en) | 2017-10-27 | 2018-10-29 | Polyethyleneimine-b-polylactic acid block copolymer, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109734921B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110560179A (en) * | 2019-09-09 | 2019-12-13 | 北京航空航天大学 | Preparation method of high-density hybrid step pore membrane for salt difference power generation |
| CN114452400A (en) * | 2022-01-29 | 2022-05-10 | 兰州大学 | Composite material nanosphere and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181053A (en) * | 2011-02-25 | 2011-09-14 | 苏州大学 | Hydrophobic-group-modified polyethyleneimine derivative and application thereof |
| CN103396557A (en) * | 2013-08-08 | 2013-11-20 | 中国药科大学 | Multifunctional cationic polymer gene vector, and preparation method and application thereof |
| CN104546709A (en) * | 2013-10-09 | 2015-04-29 | 中国医学科学院药物研究所 | pH sensitive polymer micelle for delivering medicaments |
| CN104945629A (en) * | 2014-03-25 | 2015-09-30 | 中国医学科学院药物研究所 | Reducing sensitive polyethyleneimine derivative as well as preparation method and application thereof |
| CN105646887A (en) * | 2016-01-05 | 2016-06-08 | 湖北大学 | Amphipathic high-molecular polymer, and preparation method and application thereof |
| CN107141492A (en) * | 2017-06-08 | 2017-09-08 | 华南理工大学 | One kind has target function echovirus structuring polymer vesica and its preparation and application |
-
2018
- 2018-10-29 CN CN201811264453.XA patent/CN109734921B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102181053A (en) * | 2011-02-25 | 2011-09-14 | 苏州大学 | Hydrophobic-group-modified polyethyleneimine derivative and application thereof |
| CN103396557A (en) * | 2013-08-08 | 2013-11-20 | 中国药科大学 | Multifunctional cationic polymer gene vector, and preparation method and application thereof |
| CN104546709A (en) * | 2013-10-09 | 2015-04-29 | 中国医学科学院药物研究所 | pH sensitive polymer micelle for delivering medicaments |
| CN104945629A (en) * | 2014-03-25 | 2015-09-30 | 中国医学科学院药物研究所 | Reducing sensitive polyethyleneimine derivative as well as preparation method and application thereof |
| CN105646887A (en) * | 2016-01-05 | 2016-06-08 | 湖北大学 | Amphipathic high-molecular polymer, and preparation method and application thereof |
| CN107141492A (en) * | 2017-06-08 | 2017-09-08 | 华南理工大学 | One kind has target function echovirus structuring polymer vesica and its preparation and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110560179A (en) * | 2019-09-09 | 2019-12-13 | 北京航空航天大学 | Preparation method of high-density hybrid step pore membrane for salt difference power generation |
| CN114452400A (en) * | 2022-01-29 | 2022-05-10 | 兰州大学 | Composite material nanosphere and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109734921B (en) | 2021-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy | |
| Tao et al. | Polydopamine-based surface modification of novel nanoparticle-aptamer bioconjugates for in vivo breast cancer targeting and enhanced therapeutic effects | |
| Xu et al. | High loading of hydrophilic/hydrophobic doxorubicin into polyphosphazene polymersome for breast cancer therapy | |
| Zou et al. | Drug resistance reversal in ovarian cancer cells of paclitaxel and borneol combination therapy mediated by PEG-PAMAM nanoparticles | |
| Wang et al. | Cisplatin–alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells | |
| Gao et al. | Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles | |
| Zhao et al. | Precise ratiometric loading of PTX and DOX based on redox-sensitive mixed micelles for cancer therapy | |
| US8466127B2 (en) | Pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system | |
| Ediriwickrema et al. | Multi-layered nanoparticles for combination gene and drug delivery to tumors | |
| Tang et al. | Paclitaxel prodrug based mixed micelles for tumor-targeted chemotherapy | |
| Zheng et al. | Lipid-polymer nanoparticles for folate-receptor targeting delivery of doxorubicin | |
| Gao et al. | Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects | |
| Wu et al. | Preparation and characterization of nanoparticles based on histidine–hyaluronic acid conjugates as doxorubicin carriers | |
| Tummala et al. | Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors | |
| Ma et al. | Increased active tumor targeting by an αvβ3-targeting and cell-penetrating bifunctional peptide-mediated dendrimer-based conjugate | |
| CN104530256A (en) | Hyaluronic acid-vitamin E succinate polymer as well as preparation and application thereof | |
| Liang et al. | A nanosystem of amphiphilic oligopeptide-drug conjugate actualizing both αvβ3 targeting and reduction-triggered release for maytansinoid | |
| Peng et al. | Stepwise responsive carboxymethyl chitosan-based nanoplatform for effective drug-resistant breast cancer suppression | |
| Chen et al. | Design and evaluation of dual CD44 receptor and folate receptor-targeting double-smart pH-response multifunctional nanocarrier | |
| Li et al. | Construction and anti-tumor activities of disulfide-linked docetaxel-dihydroartemisinin nanoconjugates | |
| CN109734921A (en) | A kind of polyethyleneimine-b- polylactic-acid block copolymer, preparation method and application | |
| Ye et al. | Verteporfin-loaded supramolecular micelles for enhanced cisplatin-based chemotherapy via autophagy inhibition | |
| Gowsalya et al. | Near-Infrared Light-Activated Dual Targeting with Peptide-Conjugated Mesoporous Silica Nanoparticles for Multimodal Anticancer Therapy | |
| Wang et al. | Charge-conversional click polyprodrug nanomedicine for targeted and synergistic cancer therapy | |
| Cheng et al. | Cisplatin-cross-linked and oxygen-resupply hyaluronic acid-based nanocarriers for chemo-photodynamic therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |